20:51 , Dec 19, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Mouse studies suggest inhibiting IL-1β alone or in combination with PD-1 could help treat breast cancer. In a mouse model of breast cancer, IL-1β knockdown or an anti-IL-1β antibody decreased tumor growth...
16:19 , Apr 25, 2017 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: Transgenics and knockouts SIRT6 -knockout mice could be used to screen therapies to treat AD. In postmortem temporal cortex tissue samples from AD patients, levels of SIRT6 were lower than in samples from non-AD...
07:00 , Oct 3, 2016 |  BC Week In Review  |  Company News

Ben-Gurion University, Hadassah Medical Organization, BioLineRx deal

The organization’s Hadasit Medical Research Services & Development Ltd. technology transfer arm and the university’s BGN Technologies technology transfer arm granted BioLineRx exclusive, worldwide rights to BL-1220 , a preclinical liver fibrosis and non-alcoholic steatohepatitis...
07:00 , Sep 1, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Macrophage migration inhibitory factor (MIF); superoxide dismutase 1 (SOD1)

Neurology INDICATION: Amyotrophic lateral sclerosis (ALS) Cell culture studies suggest promoting MIF expression could help treat amyotrophic lateral sclerosis (ALS). In a transgenic mutant- SOD1 mouse model of ALS, MIF knockout increased levels of insoluble...
07:00 , Apr 9, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Natural cytotoxicity triggering receptor 1 (NCR1; NKP46; CD335)

Endocrine/metabolic disease INDICATION: Diabetes Mouse studies suggest inhibiting NKP46 could help treat Type I diabetes. In mice, an antibody against mouse NKP46 decreased expression of the protein on NK cells - which are involved in...
07:00 , Apr 9, 2015 |  BC Innovations  |  Translation in Brief

Blocking β cell destruction

Most attempts to develop therapies for Type I diabetes focus on regenerating pancreatic β cells or restoring their function. A group of researchers in Israel has developed a different approach by finding an antibody that...
08:00 , Jan 15, 2015 |  BC Innovations  |  Finance

Consortia cross-talk

There's no doubt that the consortium model is here to stay, but the challenge now is to avoid creating a bureaucracy of committees with duplicate missions and redundancies of effort. The answer might be a...
07:00 , May 29, 2014 |  BC Innovations  |  Strategy

New York's biotech beginnings

New York has long produced top science but has struggled to retain and develop its own innovations. The city says it hopes a flurry of public-private partnerships, real estate developments and high-profile academic appointments will...
07:00 , Apr 17, 2014 |  BC Innovations  |  Translation in Brief

Translational tidbits

AstraZeneca plc had a busy March, announcing five new public-private partnerships and the launch of its Open Innovation website to list additional partnership opportunities ( see "Selected public-private partnerships for March 2014"). One of the...
07:00 , Mar 31, 2014 |  BC Week In Review  |  Company News

Emergent BioSolutions, Mapp Biopharmaceutical, Zalgen Labs, Ben-Gurion University of the Negev, NIH, Public Health Agency of Canada, Scripps Research Institute,

NIH's National Institute of Allergy and Infectious Disease (NIAID) awarded a consortium led by Scripps a five-year grant worth up to $28 million to develop immunotherapies for filoviruses and arenaviruses that cause severe hemorrhagic fever,...